Hwail Pharmaceutical and SupexBNP said that they have registered a patent for G-CSF (Granulocyte Colony Stimulating Factor) bio-better in the United States.
G-CSF is a drug for the treatment of neutropenia that occurs during chemotherapy. It is an essential medicine adjunct to chemotherapy. The two companies’ treatment is a bio-improved new drug that replaces amino acids in the nucleus using protein engineering technology.
“Compared with the first and second generation G-CSF treatments, the candidate substance has a faster drug expression and superior pharmacokinetics, which, in turn, provides an excellent therapeutic effect and low side effects,” the company said. “As a result, we expect a high possibility of commercial success as it has improved therapeutic effect compared to the therapeutics under development by local and global companies.”
As the neutropenia treatment global market is expected to grow to 7 trillion won ($5.8 billion) in 2017 to 12 trillion won by 2025, if approved, the two companies expect to receive a high price premium.
“By registering EU patent in the first half of this year and U.S. patent recently, the bio-business of the two companies is progressing smoothly,” a company official said. “As we registered the patents, we believe we can gain an advantageous position when discussing technology transfer with global pharmaceutical companies.”
<© Korea Biomedical Review, All rights reserved.>